Healthcare: Healthcare Provider MEH AB: Saudi Arabia

24 April 2024



US\$2.3bn Market Cap. 44.33% Free Float US\$20.8mn Avg. Daily Value traded Research Department

Madhu Appissa, CFA
Tel +966 11 836 5464, appissam@alrajhi-capital.com

Saudi German

Weak Q4, reduce TP to SAR 95/share

Q4 2023 was marred by higher than operating costs as the company recognized ECL provisions of SAR 28mn. In 9M 2023, the company booked ECL provisions of SAR 2.8mn on its receivable position of 2.1bn, which was 0.13%, negligible compared to the industry 's standard of 2.5%-3.5%. Even after the jump in Q4, the SAR 32mn ECL provisions is just 1.5% of its receivables as of 9M23, which is half of the industry standards. The rising receivable is one of our key concerns, in addition to its leverage. The company's receivable position deteriorated notably to SAR 2.3bn from SAR 1.6bn at the end of 2022. Although the company mentioned during the Q4 2023 earnings call that it has received some payments from MoH in Q1 2024, but it appears the payments are not notable enough to improve the receivables position yet. In the backdrop of high interest rates, the need for working capital requirements can hurt financial performance and offset any improvement in the top line. Moreover, we would continue to be cautious of the low ECL provisions booked by the company and consider the possibility of ECL provisions rising notably and that could be a potential downside risk to earnings and stock price.

For 2024, the company has guided for a mid-teen's topline growth and EBITDA margin of over 20%. The mid-teens growth depends on the capacity addition at Dammam (100 beds MoH approval pending), 100 beds at Makkah and 50 beds at Riyadh. In our view, the Makkah hospital ramp up could be faster than expected, while ramp up at Riyadh could take longer than expected given the rising competition in the market. Nevertheless, we estimate 13% topline growth in 2024 and EBITDA margin of 21%. As the company has communicated that they will continue with the current ECL methodology, we have not considered a spike in provisions yet. Overall, we expect net income to grow by 37% y-o-y supported by benefits of operating leverage (operating margin to improve by 190 bps y-o-y).

On the back of weak Q4 numbers and deterioration in the receivable position, we reduce our target price for the stock to SAR 95/share from SAR 113/share. In the backdrop of low double digit to mid-teens earnings growth beyond 2025, we value the stock at a blended forward P/E of 31x on 2024/2025 EPS. In terms of risks, high exposure to MoH, weak balance sheet and upcoming competition in Jeddah remain our key concerns. We maintain our neutral recommendation on the stock.

Figure 1 Summary of Q1 Estimates

(SARmn)	1Q24E	4Q23	3Q23	2Q23	1Q23	1Q24E	1Q24E
Revenue	713	720	671	624	638	y-o-y 12%	q-o-q -1%
Gross Profit	293	294	266	229	225	30%	0%
Gross Margin	41%	41%	40%	37%	35%		
Operating Profit	111	87	110	69	77	45%	27%
Operating Margin	16%	12%	16%	11%	12%		
Net Income	55	37	53	40	50	9%	49%
Net Income Margin	8%	5%	8%	6%	8%		

Source: Company Data, Al Rajhi Capital estimates

Neutral

Price Target (SAR): 95.0

Current: 95.0

Upside/Downside: at par

Valuation Multiples	23	24E	25E
P/E (x)	48.5	35.4	27.3
P/B (x)	5.8	5.0	4.2
ROE (%)	12.5	15.0	16.6

Major Shareholders

% Ownership

-6.4%

3.3%

Bait Al Batterjee Medical Company 54.7

Price Performance	1 M	3M	YTD
Absolute	-14.1%	-3.3%	7.6%

Earnings

Relative to TASI

(SARmn)	2023	2024E	2025E
Revenue	2,653	3,010	3,419
Revenue growth	23%	13%	14%
Gross profit	1,014	1,182	1,314
Gross margin	38%	39%	38%
Operating profit	342	445	492
Op. margins	13%	15%	14%
Net profit	180	247	320
Net margin	7%	8%	9%
EPS	1.96	2.68	3.48
P/E	48.5x	35.4x	27.3x
RoE	12.5%	15.0%	16.6%

Source: Company data, Al Rajhi Capital

Healthcare: Healthcare Provider MEH AB: Saudi Arabia 24 April 2024



Q1 2024 preview: We estimate revenues to decline by 1% sequentially to SAR 713mn, but +12% growth y-o-y, due to Ramadan and seasonality impact. However, the costs could stay elevated due to the pre-operating expenses related to the capacity additions. Further, the interest expense could also remain high due to working capital requirements and a further increase in the debt levels. Overall, we estimate net income to grow at a relatively lower rate than the topline due to the above-mentioned factors and come in at SAR 55mn, +9% y-o-y.

Valuations: On the back of low to mid-teens growth beyond 2025, we value the stock at a blended forward P/E of 31x on 2024/2025 EPS. In terms of risks, high exposure to MoH and weak balance sheet remain our key concerns. We maintain our neutral recommendation on the stock.

Figure 2 MEH vs Healhtcare Index (Rebased to 100)




Figure 3 Valuations

Relative Valuation (PE)	Multiples
Forward P/E	31.0x
1BF EPS	3.1
Fair value per share (SAR)	95.0
Fair value per share (SAR) CMP	95.0 95.0

Source: Bloomberg, Al Rajhi Capital

Source: Company Data, Al Rajhi Capital

Healthcare: Healthcare Provider MEH AB: Saudi Arabia

24 April 2024



Financials

Figure 4 Income Statement

Income Statement (SAR mn)	2023	2024E	2025E
Sales	2,653	3,010	3,419
y-o-y growth	23.3%	13.4%	13.6%
Cost of Sales	(1,639)	(1,828)	(2,105)
y-o-y growth	11.3%	11.5%	15.2%
Gross Income	1,014	1,182	1,314
y-o-y growth	49.2%	16.5%	11.2%
margins	38.2%	39.3%	38.4%
Employee costs	(395)	(476)	(532)
Selling and distribution expenses	(51)	(51)	(51)
Administrative expenses	(226)	(211)	(239)
Operating Income	342	445	492
y-o-y growth	144.0%	29.8%	10.6%
margins	12.9%	14.8%	14.4%
Investments and other	15	15	15
Financing Expense	(156)	(175)	(155)
Net income before tax	202	284	351
Zakat & Tax	(18)	(34)	(28)
tax rate	8.9%	12.0%	8.0%
Net Profit Before Minority Interest	184	250	323
Minority Interest (loss)/profit	(3)	(3)	(3)
Net Income	180	247	320
y-o-y growth	139.7%	37.0%	29.6%
margins	6.8%	8.2%	9.4%
EPS	2.0	2.7	3.5

Source: Al Rajhi Capital estimates

Figure 6 Cash Flow Statement

Cash flow statement (SAR mn)	2023	2024E	2025E
Net cash flows from Operating Activities	191	626	553
Cash Flows from Investing Activities	(242)	(289)	(291)
Cash Flows from Financing Activities	80	(325)	(268)

Source: Al Rajhi Capital estimates

Figure 5 Balance sheet

Balance Sheet (SAR mn) 2023 2024E 2025E Assets Cash & Cash Equivalents 44 56 50 Receivables, Net 2,301 2,408 2,667 Inventory 75 85 96 Other 155 155 155 Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,1				
Cash & Cash Equivalents 44 56 50 Receivables, Net 2,301 2,408 2,667 Inventory 75 85 96 Other 155 155 155 Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 <td>Balance Sheet (SAR mn)</td> <td>2023</td> <td>2024E</td> <td>2025E</td>	Balance Sheet (SAR mn)	2023	2024E	2025E
Receivables, Net 2,301 2,408 2,667 Inventory 75 85 96 Other 155 155 155 Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 <td>Assets</td> <td></td> <td></td> <td></td>	Assets			
Inventory 75 85 96 Other 155 155 155 Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9	Cash & Cash Equivalents	44	56	50
Other 155 155 155 Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240	Receivables, Net	2,301	2,408	2,667
Total Current Assets 2,575 2,704 2,968 Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities	Inventory	75	85	96
Fixed Assets 2,502 2,587 2,663 Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 73 Accrued expenses 291 329 372 Zakat payable 18 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Owners Equity	Other	155	155	155
Right-of-use asset 55 57 58 Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124 <td>Total Current Assets</td> <td>2,575</td> <td>2,704</td> <td>2,968</td>	Total Current Assets	2,575	2,704	2,968
Intangibles 31 25 20 Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Owners Equity 1,565 1,815 2,124	Fixed Assets	2,502	2,587	2,663
Total Non-Current Assets 2,598 2,679 2,752 Total Assets 5,173 5,383 5,719 Liabilities Short term debt 1,116 1,116 1,116 1,168 Other financial liab 6 6 6 6 6 Trade payables 559 631 713 713 713 714 714 715 <th< td=""><td>Right-of-use asset</td><td>55</td><td>57</td><td>58</td></th<>	Right-of-use asset	55	57	58
Liabilities 5,173 5,383 5,719 Short term debt 1,116 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Intangibles	31	25	20
Liabilities Short term debt 1,116 1,116 1,116 1,168 Other financial liab 6 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Total Non-Current Assets	2,598	2,679	2,752
Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Total Assets	5,173	5,383	5,719
Short term debt 1,116 1,116 1,168 Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124				
Other financial liab 6 6 6 Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Liabilities			
Trade payables 559 631 713 Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Short term debt	1,116	1,116	1,168
Accrued expenses 291 329 372 Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Other financial liab	6	6	6
Zakat payable 18 18 18 Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Trade payables	559	631	713
Total Current liabilities 2,003 2,112 2,290 Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Accrued expenses	291	329	372
Long-Term Debt 1,310 1,160 1,010 Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Zakat payable	18	18	18
Long-term lease liabilities 46 46 46 Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Total Current liabilities	2,003	2,112	2,290
Deferred income 9 9 9 Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Long-Term Debt	1,310	1,160	1,010
Employee's end of service benefit 240 240 240 Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Long-term lease liabilities	46	46	46
Total Non-Current Liabilities 1,606 1,456 1,305 Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Deferred income	9	9	9
Total Liabilities 3,608 3,568 3,595 Total Owners Equity 1,565 1,815 2,124	Employee's end of service benefit	240	240	240
Total Owners Equity 1,565 1,815 2,124	Total Non-Current Liabilities	1,606	1,456	1,305
	Total Liabilities	3,608	3,568	3,595
Total Equity and Liabilities 5,173 5,383 5,719	Total Owners Equity	1,565	1,815	2,124
	Total Equity and Liabilities	5,173	5,383	5,719

Source: Al Rajhi Capital estimates

Healthcare: Healthcare Provider MEH AB: Saudi Arabia 24 April 2024



IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Raihi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Raihi,

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Healthcare: Healthcare Provider MEH AB: Saudi Arabia 24 April 2024



Disclaimer and additional disclosures for Equity Research

Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

Contact us

Mazen AlSudairi, CFA, CMT Head of Research Tel: +966 11 836 5468

Email: alsudairim@alrajhi-capital.com

Al Rajhi Capital

Research Department Head Office, King Fahad Road P.O. Box 5561, Riyadh 11432 Kingdom of Saudi Arabia Email: research@alrajhi-capital.com

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37